Capital International Investors cut its holdings in Eli Lilly and Company (NYSE:LLY) by 3.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,092,849 shares of the company’s stock after selling 125,385 shares during the period. Capital International Investors owned 0.39% of Eli Lilly and worth $336,841,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. AHL Partners LLP increased its stake in Eli Lilly and by 127.4% during the second quarter. AHL Partners LLP now owns 67,347 shares of the company’s stock valued at $5,543,000 after acquiring an additional 37,725 shares during the period. Salem Investment Counselors Inc. increased its stake in Eli Lilly and by 25.9% during the second quarter. Salem Investment Counselors Inc. now owns 45,060 shares of the company’s stock valued at $3,708,000 after acquiring an additional 9,260 shares during the period. Sun Life Financial INC increased its stake in Eli Lilly and by 15,975.0% during the second quarter. Sun Life Financial INC now owns 7,073 shares of the company’s stock valued at $582,000 after acquiring an additional 7,029 shares during the period. Institute for Wealth Management LLC. bought a new position in Eli Lilly and during the second quarter valued at about $1,063,000. Finally, Clinton Group Inc. increased its stake in Eli Lilly and by 26.0% during the second quarter. Clinton Group Inc. now owns 52,822 shares of the company’s stock valued at $4,347,000 after acquiring an additional 10,914 shares during the period. Hedge funds and other institutional investors own 76.61% of the company’s stock.
Eli Lilly and Company (NYSE:LLY) opened at $83.18 on Tuesday. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $89.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $91,590.00, a price-to-earnings ratio of 20.27, a price-to-earnings-growth ratio of 1.83 and a beta of 0.34.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.50%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio is 99.05%.
Several brokerages recently issued reports on LLY. BMO Capital Markets restated a “sell” rating and set a $73.00 price target on shares of Eli Lilly and in a research note on Friday, August 4th. TheStreet upgraded Eli Lilly and from a “c+” rating to a “b+” rating in a research note on Tuesday, July 25th. Leerink Swann downgraded Eli Lilly and from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $93.00 to $90.00 in a report on Wednesday, July 26th. Cowen and Company reaffirmed a “buy” rating and set a $95.00 price objective on shares of Eli Lilly and in a report on Wednesday, October 4th. Finally, UBS AG downgraded Eli Lilly and to a “hold” rating and set a $85.00 price objective on the stock. in a report on Wednesday, July 26th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the company’s stock. Eli Lilly and currently has an average rating of “Hold” and a consensus price target of $89.76.
In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the transaction, the senior vice president now owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 180,000 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00. Following the transaction, the insider now directly owns 123,865,804 shares in the company, valued at approximately $10,040,562,072.24. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 772,003 shares of company stock worth $64,837,441. Company insiders own 0.20% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Eli Lilly and Company (LLY) Stake Lowered by Capital International Investors” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://sportsperspectives.com/2017/11/21/eli-lilly-and-company-lly-stake-lowered-by-capital-international-investors.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.